| Publications | DOI=10.1159/000407025
Helson L., Verma M., Helson C.
Vitamin E and human neuroblastoma.
(In) Modulation and mediation of cancer by vitamins; Meyskens F.L., Prasad K.N. (eds.); pp.258-265; Karger; Basel (1983) PubMed=6610792; DOI=10.1093/jnci/73.1.51
Sugimoto T., Tatsumi E., Kemshead J.T., Helson L., Green A.A., Minowada J.
Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies.
J. Natl. Cancer Inst. 73:51-57(1984) PubMed=2987426; DOI=10.1007/BF00165170
Helson L., Helson C.
Human neuroblastoma cells and 13-cis-retinoic acid.
J. Neurooncol. 3:39-41(1985) DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994) PubMed=7838528
Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995) PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7
Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.
Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Cancer Genet. Cytogenet. 97:135-142(1997) DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999) PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001) PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002) PubMed=12702577
Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003) PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005) PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006) PubMed=17506115; DOI=10.1002/nbm.1181
Peet A.C., McConville C.M., Wilson M.P., Levine B.A., Reed M., Dyer S.A., Edwards E.C., Strachan M.C., McMullan D.J., Wilkes T.M., Grundy R.G.
1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines.
NMR Biomed. 20:692-700(2007) PubMed=18534018; DOI=10.1186/1476-4598-7-50
Combaret V., Boyault S., Iacono I., Brejon S., Rousseau R., Puisieux A.
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Mol. Cancer 7:50.1-50.12(2008) PubMed=18724359; DOI=10.1038/nature07261
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., LaQuaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008) PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010) PubMed=20655465; DOI=10.1016/j.cell.2010.06.004
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010) PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012) PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012) PubMed=23202128; DOI=10.1038/ng.2493
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013) PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013) PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016) PubMed=28192521; DOI=10.1371/journal.pone.0172140
Saintas E., Abrahams L., Ahmad G.T., Ajakaiye A.-O.M., AlHumaidi A.S.H.A.M., Ashmore-Harris C., Clark I., Dura U.K., Fixmer C.N., Ike-Morris C., Mato Prado M., McCullough D., Mishra S., Scholer K.M.U., Timur H., Williamson M.D.C., Alatsatianos M., Bahsoun B., Blackburn E., Hogwood C.E., Lithgow P.E., Rowe M., Yiangou L., Rothweiler F., Cinatl J. Jr., Zehner R., Baines A.J., Garrett M.D., Gourlay C.W., Griffin D.K., Gullick W.J., Hargreaves E., Howard M.J., Lloyd D.R., Rossman J.S., Smales C.M., Tsaousis A.D., von der Haar T., Wass M.N., Michaelis M.
Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
PLoS ONE 12:E0172140-E0172140(2017) PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017) PubMed=30459281; DOI=10.1126/scisignal.aar5680
Van den Eynden J., Umapathy G., Ashouri A., Cervantes-Madrid D., Szydzik J., Ruuth K., Koster J., Larsson E., Guan J.-K., Palmer R.H., Hallberg B.
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Sci. Signal. 11:eaar5680.1-eaar5680.16(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020) PubMed=33921066; DOI=10.3390/cancers13081909
Siaw J.T., Gabre J.L., Uckun E., Vigny M., Zhang W.-C., Van den Eynden J., Hallberg B., Palmer R.H., Guan J.-K.
Loss of RET promotes mesenchymal identity in neuroblastoma cells.
Cancers (Basel) 13:1909.1-1909.25(2021) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022) |
|---|
